Gennigens C, Jerusalem G
Chargé de Cours, Service d'Oncologie médicale, CHU de Liège.
Rev Med Liege. 2012 Jul-Aug;67(7-8):437-42.
Renal cell carcinoma accounts for 3% of all malignant tumors. Until a few years ago, immunotherapy (Interferon and/or Interleukin-2) was the only approved systemic treatment in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF and VEGFR inhibitors. They are now the standard treatment in first and second line. Pazopanib, a VEGFR tyrosine kinase inhibitor, is one of the treatment options recommended for patients with metastatic renal cell carcinoma, in first line and after cytokines failure. Since more recently, pazopanib is also approved in the treatment of metastatic soft tissue sarcoma, after failure of at least one line of chemoterapy. In this paper, we will review the mechanism of action and the clinical results of pazopanib in renal cell carcinoma and sarcoma.
肾细胞癌占所有恶性肿瘤的3%。直到几年前，免疫疗法（干扰素和/或白细胞介素-2）还是转移性情况下唯一获批的全身治疗方法。对肾细胞癌生物学的深入了解使人们关注到血管生成的重要作用。已经开发了几种针对血管生成的策略，包括VEGF和VEGFR抑制剂。它们现在是一线和二线治疗的标准方法。帕唑帕尼是一种VEGFR酪氨酸激酶抑制剂，是推荐用于一线及细胞因子治疗失败后的转移性肾细胞癌患者的治疗选择之一。最近，帕唑帕尼在至少一线化疗失败后，也被批准用于治疗转移性软组织肉瘤。在本文中，我们将综述帕唑帕尼在肾细胞癌和肉瘤中的作用机制及临床结果。
